Search Result "Myelofibrosis"
Current and Emerging Therapies in Primary Myelofibrosis
Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 12 Issue: 1 Year: 2012 Page: 6-20
Author(s): Sabarish Ayyappan,Murali Janakiram,Radha Raghupathy
Epigenetic Modifications: New Therapeutic Targets in Primary Myelofibrosis
Journal: Current Stem Cell Research & Therapy
Volume: 4 Issue: 4 Year: 2009 Page: 281-286
Author(s): Kirugaval Hemavathy, Jen C. Wang
First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor forthe Treatment of Patients with Myelofibrosis
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 23 Issue: 12 Year: 2023 Page: 1355-1360
Author(s): Surya K. De
Molecular Advances Toward the Understanding of the Patho-Biology of Idiopathic Myelofibrosis
Journal: Current Immunology Reviews
Volume: 2 Issue: 2 Year: 2006 Page: 169-186
Author(s): Anna R. Migliaccio, Alessandro M. Vannucchi, Giovanni Migliaccio, Ronald Hoffman
Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Journal: Current Cancer Therapy Reviews
Volume: 8 Issue: 1 Year: 2012 Page: 14-29
Author(s): Robert P. Hasserjian
JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 12 Issue: 9 Year: 2012 Page: 1098-1109
Author(s): Fabio P. S. Santos,Srdan Verstovsek
The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders
Journal: Current Drug Targets
Volume: 8 Issue: 2 Year: 2007 Page: 247-256
Author(s): Hans Carl Hasselbalch, Caroline H. Riley
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia BlasticCrisis in a Patient with Unusual Primary Myelofibrosis Characteristics; ACase Report
Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 22 Issue: 2 Year: 2024 Page: 240-245
Author(s):
Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
Journal: Current Medicinal Chemistry
Volume: 19 Issue: 2 Year: 2012 Page: 4399-4413
Author(s): J. Mascarenhas, T. I. Mughal, S. Verstovsek
Immunotherapy for Myeloproliferative Neoplasms (MPN)
Journal: Current Cancer Drug Targets
Volume: 11 Issue: 1 Year: 2011 Page: 72-84
Author(s): Susanne Hofmann, Anna Babiak, Jochen Greiner